New study: LIB-01 assumed to be the next generation of potency drugs

Uppsala, November 15, 2022. Dicot's latest study of the mechanism of action of LIB-01, i.e., how the drug affects the body to achieve the desired effect, shows that it differentiates from today's potency drugs. This means that LIB-01 can be assumed to represent a new generation of potency drugs.

Dicot is developing a modern potency drug to treat erectile dysfunction and premature ejaculation better than existing medicines. As part of the long-term development work, studies are underway to map LIB-01's mechanism of action - that is, how the drug affects underlying processes in the body so that the desired effect occurs.

Results from a recent ex vivo study show that the mechanism of action of LIB-01 differentiates from today's potency drugs such as e.g., Viagra. These are significant results as today's potency drugs, with their mechanism of action, do not work optimally for all patients whereof approximately 35% do not have sufficient effect and many report unwanted side effects.

"The fact that we now can postulate that the mechanism of LIB-01 differentiates from current ED drugs is of great importance, and an indication that LIB-01 may represent a new generation of ED drugs", comments Professor Francois Giuliano, urologist specialized in sexual medicine and founder of Pelvipharm.

"With a different mechanism of action than today's drugs, we have a great potential to show that LIB-01 can treat sexual dysfunctions better than current treatments," says Elin Trampe, CEO at Dicot.

For further information, please contact:

Elin Trampe, CEO
Tel: +46 739 80 14 08
[email protected]

About Dicot AB

Dicot is developing the drug candidate LIB-01, which will be a potency agent to better treat erectile dysfunction and premature ejaculation. The ambition is to create a drug with significantly longer effect and far fewer side effects, compared to those on the market. Today, at least 500 million men suffer from these sexual dysfunctions and the market is valued at SEK 50 billion. Research and development are conducted under own auspices up to phase 2 studies. Thereafter, Dicot's intention is to form strategic alliances, or alternatively carry out a trade sale, with larger, established pharmaceutical companies to be able to introduce LIB-01 on the world market.

Dicot is listed on Spotlight Stock Market and has approximately 3,300 shareholders. For more information, please visit